Evidence map›Paper›PMID 42518095›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026

The economic burden of neurological disorders in Europe - COIN-Eu: Study design and analytic framework.

Uwe Siebert, M Arvandi, P Boon, C L A Bassetti, T Berger, E Moro, M Montes-Martinez, L Welter, C Kruse, M Konti and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The global cost of schizophrenia: a health economic modelling study.International journal of mental health systems · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Uwe SiebertInstitute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment, UMIT TIROL - University for Health Sciences and Technology, Eduard-Wallnoefer-Zentrum 1, Hall in Tirol, A-6060, Austria. uwe.siebert@umit-tirol.at.ORCID http://orcid.org/0000-0001-6425-7671
M ArvandiInstitute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment, UMIT TIROL - University for Health Sciences and Technology, Eduard-Wallnoefer-Zentrum 1, Hall in Tirol, A-6060, Austria.
P BoonDepartment of Neurology, 4Brain Ghent University Hospital & Ghent University, Ghent, Belgium.
C L A BassettiMedical Faculty, Neurology Department, University of Bern, Inselspital, Bern, Switzerland.
T BergerDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
E MoroCHU of Grenoble, Division of Neurology, Grenoble Alpes University, Grenoble Institute of Neurosciences, Grenoble, France.
M Montes-MartinezDepartment of Geriatric Medicine, University Duisburg-Essen, Essen, Germany.
L WelterDepartment of Geriatric Medicine, University Duisburg-Essen, Essen, Germany.
C KruseDepartment of Geriatric Medicine, University Duisburg-Essen, Essen, Germany.
M KontiEuropean Academy of Neurology, Vienna, Austria.
M LolichEuropean Academy of Neurology, Vienna, Austria.
S PuntscherInstitute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment, UMIT TIROL - University for Health Sciences and Technology, Eduard-Wallnoefer-Zentrum 1, Hall in Tirol, A-6060, Austria.
N MühlbergerInstitute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment, UMIT TIROL - University for Health Sciences and Technology, Eduard-Wallnoefer-Zentrum 1, Hall in Tirol, A-6060, Austria.
G DeuschlDepartment of Neurology, UKSH, Kiel Campus and Christian-Albrechts-University, Kiel, Germany.
R DodelDepartment of Geriatric Medicine, University Duisburg-Essen, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNeurological disorders are a leading cause of disability, morbidity, and mortality globally, imposing a substantial and growing economic burden. In Europe, several factors including demographic aging and improved diagnostics have increased the prevalence of these conditions. Despite their significant societal impact, comprehensive and comparable estimates of the economic burden of neurological disorders across Europe remain limited. Existing studies are mostly outdated, disease-specific, or geographically narrow. The Cost Of Illness in Neurology in EUrope (COIN-Eu) study addresses this gap by developing a standardized framework to assess the disease- and country-specific economic burden of major neurological disorders across all 47 member countries of the European Academy of Neurology (EAN).

methodsThis burden-of-disease study employs a prevalence-based approach to estimate three key economic measures per disorder and country: (1) annual per-patient costs by cost type, (2) total annual costs on a national level, and (3) relative total costs as a percentage of GDP. The study includes twelve major neurological disorder groups affecting adults (≥ 20 years). Epidemiological data are primarily sourced from the Global Burden of Disease Study 2021, supplemented by systematic literature reviews where necessary. Cost data are extracted from systematic reviews of peer-reviewed publications and converted to 2019 Euros using standardized procedures. Data gaps are addressed through structured imputations based on income group stratification. Final estimates are validated by an expert panel from the EAN.

resultsThe framework enables the generation of harmonized cost estimates across countries and disorders, accounting for direct and informal care costs and indirect costs. Expert review ensured plausibility and consistency of the results.

conclusionThe COIN-Eu study framework provides a comprehensive and transparent methodology to estimate the economic burden of neurological disorders in Europe. It facilitates evidence-based health policy planning, highlights data gaps, and supports future cross-national burden-of-disease assessments in neurology and beyond.

Indexed as

Brain healthBurdenCost of illnessCostsNeurological disordersNeurologyPublic health

Identifiers

PMID42518095

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.